Compare RDVT & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDVT | TBPH |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.2M | 908.9M |
| IPO Year | 2017 | 2013 |
| Metric | RDVT | TBPH |
|---|---|---|
| Price | $69.26 | $16.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $62.00 | $18.40 |
| AVG Volume (30 Days) | 160.0K | ★ 815.7K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 82.00 | ★ 279.13 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $90,252,000.00 | $15,386,000.00 |
| Revenue This Year | $16.31 | $8.46 |
| Revenue Next Year | $13.83 | N/A |
| P/E Ratio | $218.40 | ★ N/A |
| Revenue Growth | ★ 20.03 | N/A |
| 52 Week Low | $33.40 | $10.82 |
| 52 Week High | $67.68 | $21.03 |
| Indicator | RDVT | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 81.64 | 54.48 |
| Support Level | $50.66 | $16.12 |
| Resistance Level | N/A | $17.21 |
| Average True Range (ATR) | 2.66 | 0.34 |
| MACD | 0.94 | 0.01 |
| Stochastic Oscillator | 92.78 | 48.69 |
Red Violet Inc builds proprietary technologies and applies analytical capabilities to deliver identity intelligence. The company's solutions enable the real-time identification and location of people, businesses, assets, and their interrelationships. These solutions are used for purposes including identity verification, risk mitigation, due diligence, fraud detection and prevention, regulatory compliance, and customer acquisition. Its cloud-native, AI-enabled identity intelligence platform, CORE, is purpose-built for the enterprise, yet flexible enough for organizations of all sizes, bringing clarity to massive datasets by transforming data into intelligence. The company generates substantially all of its revenue from licensing its solutions.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.